CorMedix Inc (NASDAQ: CRMD) on Tuesday, plunged -0.51% from the previous trading day, before settling in for the closing price of $9.90. Within the past 52 weeks, CRMD’s price has moved between $2.89 and $13.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -47.11%. The company achieved an average annual earnings per share of 45.05%. With a float of $59.76 million, this company’s outstanding shares have now reached $60.68 million.
Let’s determine the extent of company efficiency that accounts for 82 employees. In terms of profitability, gross margin is 83.54%, operating margin of -405.54%, and the pretax margin is -378.34%.
CorMedix Inc (CRMD) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CorMedix Inc is 1.51%, while institutional ownership is 31.41%. The most recent insider transaction that took place on Nov 14 ’24, was worth 1,565,670. In this transaction EVP of this company sold 140,027 shares at a rate of $11.18, taking the stock ownership to the 45,397 shares. Before that another transaction happened on Nov 14 ’24, when Company’s Officer proposed sale 140,027 for $11.12, making the entire transaction worth $1,556,416.
CorMedix Inc (CRMD) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.26 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.2) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.05% per share during the next fiscal year.
CorMedix Inc (NASDAQ: CRMD) Trading Performance Indicators
CorMedix Inc (CRMD) is currently performing well based on its current performance indicators. A quick ratio of 3.60 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 48.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.36 in one year’s time.
Technical Analysis of CorMedix Inc (CRMD)
Looking closely at CorMedix Inc (NASDAQ: CRMD), its last 5-days average volume was 0.78 million, which is a jump from its year-to-date volume of 0.74 million. As of the previous 9 days, the stock’s Stochastic %D was 22.21%. Additionally, its Average True Range was 0.65.
During the past 100 days, CorMedix Inc’s (CRMD) raw stochastic average was set at 60.94%, which indicates a significant increase from 16.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.85% in the past 14 days, which was lower than the 83.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.25, while its 200-day Moving Average is $6.21. However, in the short run, CorMedix Inc’s stock first resistance to watch stands at $10.03. Second resistance stands at $10.20. The third major resistance level sits at $10.52. If the price goes on to break the first support level at $9.54, it is likely to go to the next support level at $9.22. Now, if the price goes above the second support level, the third support stands at $9.05.
CorMedix Inc (NASDAQ: CRMD) Key Stats
Market capitalization of the company is 597.67 million based on 60,677K outstanding shares. Right now, sales total 0 K and income totals -46,340 K. The company made 11,460 K in profit during its latest quarter, and -2,780 K in sales during its previous quarter.
